NLS Pharmaceutics AG (NLSP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NLS Pharmaceutics AG (NLSP) has a cash flow conversion efficiency ratio of -0.719x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($2.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NLS Pharmaceutics AG net asset quality index to measure how much of total assets are equity-financed.
NLS Pharmaceutics AG - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NLS Pharmaceutics AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NLS Pharmaceutics AG cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
NLS Pharmaceutics AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NLS Pharmaceutics AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
N/A |
|
Australasian Metals Ltd
AU:A8G
|
-0.053x |
|
EAM Solar ASA
OL:EAM
|
-0.359x |
|
AM Resources Corp
V:AMR
|
-3.051x |
|
LUPAKA GOLD CORP.
F:LQPA
|
0.173x |
|
Cre8 Enterprise Limited Class A Ordinary Shares
NASDAQ:CRE
|
0.030x |
|
Wi2Wi Corporation
V:YTY
|
-0.128x |
|
International Biotechnology Trust plc
LSE:IBT
|
0.126x |
Annual Cash Flow Conversion Efficiency for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual cash flow conversion efficiency of NLS Pharmaceutics AG from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NLSP market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.41 Million | $-4.27 Million | -3.035x | -376.81% |
| 2023-12-31 | $-8.83 Million | $-9.68 Million | 1.096x | +125.92% |
| 2022-12-31 | $3.28 Million | $-13.88 Million | -4.230x | +84.64% |
| 2021-12-31 | $542.39K | $-14.94 Million | -27.538x | -34018.81% |
| 2020-12-31 | $-8.98 Million | $-729.39K | 0.081x | +163.67% |
| 2019-12-31 | $-6.17 Million | $-190.01K | 0.031x | -90.07% |
| 2018-12-31 | $-8.81 Million | $-2.73 Million | 0.310x | -55.95% |
| 2017-12-31 | $-7.72 Million | $-5.43 Million | 0.704x | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more